UNLABELLED Non-alcoholic fatty liver disease has an increasing prevalence in Western countries, affecting up to 20% of the population. OBJECTIVE The aim of this project was to systematically review and summarise the genetic association studies that investigate possible genetic influences that confer susceptibility to non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. DESIG...

objective(s):non-alcoholic steatohepatitis (nash), is an important component of non-alcoholic fatty liver disease (nafld) spectrum, which progresses to the end stage liver disease, if not diagnosed and treated properly. the disproportionate production of pro- and anti-inflammatory adipokines secreted from fat contributes to the pathogenesis of nash. in this study, the comparative effect of piog...

Non-alcoholic steatohepatitis has emerged as a major public health problem, and the burden of non-alcoholic cirrhosis is projected to increase by 64%-156% 2030. The threat aggravated fact that are currently no approved drugs for treatment steatohepatitis. In this paper, we review main challenges drug development in patients with cirrhosis, describe opportunities brought advances understanding c...

Non-alcoholic fatty liver (NAFL) is one of the most common liver diseases encountered in the United States and Europe. This term refers to a spectrum of hepatic pathology that resembles alcoholic liver disease, but appears in individuals who have low or negligible alcohol consumption. Initially the term non-alcoholic steatohepatitis (NASH) was employed by Ludwig et al. in 1980 to describe a syn...

context non-alcoholic fatty liver disease (nafld) is a chronic liver disease, with 5-10% of liver having extra fat. increase in its prevalence in all age groups is linked with obesity and type ii diabetes. the treatment of nafld remains controversial. a growing body of evidence suggests a relation between overgrowth of gut microbiota with nafld and non-alcoholic steatohepatitis (nash). the obje...

Non-alcoholic fatty liver disease (NAFLD) which includes steatosis and steatohepatitis, in particular non-alcoholic steatohepatitis (NASH), is a rising health problem world-wide and should be separated from alcoholic steatohepatitis (ASH). NAFLD is regarded as hepatic manifestation of the metabolic syndrome (MetSy), being tightly linked to obesity and type 2 diabetes mellitus (T2DM). Developmen...

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes diseases: 25% population European countries have signs NAFLD, 10–20% patients with steatosis develop an inflammatory process (non-alcoholic steatohepatitis), which, if not treated, can transform into fibrosis and cirrhosis. In people, NAFLD diagnosed, prognosis inaccurate, there are no licensed methods treating disease. ...

Hepatic steatosis and steatohepatitis are common histologic findings that can be caused by multiple etiologies. The three most frequent causes for steatosis/steatohepatitis are alcohol (alcoholic steatohepatitis, ASH), obesity/metabolic syndrome (nonalcoholic steatohepatitis, NASH), and environmental toxicants (toxicant-associated steatohepatitis, TASH). Hepatic steatosis is an early occurrence...